Advertisement

Picture BIO Deutschland CFO-Gipfel 2017 Hannover April 600x60px
Document › Details

Merck KGaA. (1/8/14). "Press Release: Merck Serono Appoints Steven Hildemann as Global Chief Medical Officer". Darmstadt.

Organisations Organisation Merck Serono (division of Merck KGaA)
  Group Merck (DE) (Group)
  Organisation 2 Merck, Sharp & Dohme
  Group Merck (US) (Group)
Products Product pharmaceutical
  Product 2 biopharmaceutical
Persons Person Hildemann, Steven (Merck (DE) 201401– Global CMO at Merck Serono before MSD/Merck US)
  Person 2 Jenkins, Annalisa (TransCelerate BioParma 201402 Chair of Board of Directors before Merck Serono + BMS)
     


Dr. Hildemann brings more than 20 years of experience to Merck Serono, across academic medicine and the pharmaceutical industry


Merck Serono, the biopharmaceutical division of Merck, today announced the appointment of Steven Hildemann, MD, PhD, as Global Chief Medical Officer (CMO) and Head of Global Medical and Safety for the Merck Serono division. Dr. Hildemann is a board-certified Internist and Cardiologist trained in the U.S. and Germany. In his role as CMO, Hildemann will be based in Darmstadt, Germany, and report to the Global Head of Research & Development of Merck Serono, Dr. Annalisa Jenkins.

As CMO, Hildemann will be responsible for Global Medical Affairs, Global Drug Safety and External Scientific Affairs for Merck Serono. In this capacity, one of his primary responsibilities will be to support the safe and appropriate use of and access to Merck Serono medicines. He will also serve as a member of the R&D Executive Leadership Team.

"Dr. Hildemann's academic and industry experience is very impressive, and he is a valued addition to our organization and the R&D Leadership Team," said Annalisa Jenkins, Global Head of Research and Development at Merck Serono. "His patient-centric focus is well-aligned with our commitment to delivering differentiated new medicines to people living with unmet medical needs around the world."

Hildemann will also be responsible for medical governance in his role as Global CMO, chairing the Medical Safety and Ethics Board and the Bioethics Committee at Merck Serono. As a senior leader, he will support collaboration and partnership across the continuum of R&D and commercial.

Prior to joining Merck Serono, Hildemann was Associate Vice President, Global Clinical Trial Operations Europe, MSD (in the U.S.: Merck & Co). In this capacity, he was responsible for the execution of all early- and late-stage development programs, including life cycle management, in Europe across all of MSD's therapeutic areas with a focus on Infectious Diseases, Central Nervous System Disorders and Oncology.

Hildemann joined the pharmaceutical industry in 1998 as the country medical director cardiovascular for Searle in Germany. After the merger with Pharmacia, he progressed to positions of increasing responsibility and in 2002 moved to New Jersey / U.S. as the Senior Global Medical Director Cardiovascular for Pharmacia, and later Pfizer. In this role, he co-designed and implemented a global Phase IIIb / IV program for the NCE-Eplerenone. This medicine is now included in current treatment guidelines around the world and a standard-of-care in patients with moderate and severe heart failure.

In 2004, Hildemann joined Schering-Plough (SP) as the country medical director in Germany. In this role, one of his joint responsibilities was the world-wide first launch of a novel combination in lipid-therapy (Ezetimibe-Simvastatin) in partnership with MSD. In 2006, Hildemann led the design and full implementation of major global change efforts, such as Global Clinical Harmonization at Schering-Plough and global integration activities for MSD-Research-Laboratories during the merger of SP and MSD.

Dr. Hildemann spent the first 10 years of his career in academic medicine.

Throughout his industry work, Hildemann has maintained part-time clinical practice and academic teaching as a basis to closely serve patients, physicians and customers with meaningful advances through innovative medicines. He is a member and fellow of renowned international medical societies and serves on faculty as an associate professor of medicine at the University of Freiburg, Germany.

Dr. Hildemann succeeds Dr. Florian Bieber in the CMO role at Merck Serono. Bieber left Merck Serono in December, 2013 to pursue other opportunities.

Hildemann is native to Germany, but has spent a good portion of his life in the United States. He is 51 years old.


About Merck Serono

Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.
For more information, please visit www.merckserono.com.


All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website www.merckgroup.com/media. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.


Merck is a leading pharmaceutical, chemical and life science company with total revenues of € 11.2 billion in 2012, a history that began in 1668, and a future shaped by approx. 38,000 employees in 66 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

   
Record changed: 2016-03-20

Advertisement

Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 600x60px

More documents for Merck (DE) (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland CFO-Gipfel 2017 Hannover April 120x240px Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 120x240px Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px